← Back to Screener
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)
Price$13.12
Favorite Metrics
Price vs S&P 500 (26W)-20.62%
Price vs S&P 500 (4W)-31.50%
Market Capitalization$75.68M
P/E Ratio (Annual)11.10x
All Metrics
Book Value / Share (Quarterly)$1.59
P/TBV (Annual)5.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.82%
Cash Flow / Share (Quarterly)$-2.10
Price vs S&P 500 (YTD)-38.69%
Gross Margin (TTM)66.92%
Net Profit Margin (TTM)10.77%
EPS (TTM)$0.17
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$0.17
Revenue Growth (5Y)6.77%
EPS (Annual)$0.24
Dividend / Share (Annual)$0.02
ROI (Annual)6.23%
Gross Margin (Annual)66.92%
Net Profit Margin (5Y Avg)-69.82%
Cash / Share (Quarterly)$2.53
P/E Basic Excl Extra (TTM)11.10x
Revenue Growth QoQ (YoY)6.34%
P/E Normalized (Annual)11.10x
ROA (Last FY)3.67%
Revenue Growth TTM (YoY)9.69%
EBITD / Share (TTM)$-0.72
ROE (5Y Avg)-144.95%
Operating Margin (TTM)-68.39%
Cash Flow / Share (Annual)$-2.10
P/B Ratio1.52x
P/B Ratio (Quarterly)2.28x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.88x
Net Interest Coverage (TTM)-3.18x
ROA (TTM)3.87%
EPS Incl Extra (Annual)$0.24
Current Ratio (Annual)2.49x
Quick Ratio (Quarterly)2.20x
3-Month Avg Trading Volume0.86M
52-Week Price Return54.61%
P/E Incl Extra (TTM)11.10x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.71
P/S Ratio (Annual)1.20x
Asset Turnover (Annual)0.34x
52-Week High$4.53
Operating Margin (5Y Avg)-194.96%
EPS Excl Extra (Annual)$0.24
CapEx CAGR (5Y)25.86%
Tangible BV CAGR (5Y)3.44%
26-Week Price Return-16.07%
Quick Ratio (Annual)2.20x
13-Week Price Return-39.74%
Total Debt / Equity (Annual)1.19x
Current Ratio (Quarterly)2.49x
Enterprise Value$55.797
Revenue / Share Growth (5Y)-24.91%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-36.92%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)-53.01%
Cash / Share (Annual)$2.53
3-Month Return Std Dev73.36%
Gross Margin (5Y Avg)62.38%
Net Income / Employee (TTM)$0
ROE (Last FY)13.66%
Net Interest Coverage (Annual)-3.20x
EPS Basic Excl Extra (Annual)$0.24
Receivables Turnover (TTM)3.16x
Total Debt / Equity (Quarterly)1.19x
EPS Incl Extra (TTM)$0.17
Receivables Turnover (Annual)3.16x
ROI (TTM)6.87%
Dividend Growth Rate (5Y)-54.94%
P/S Ratio (TTM)1.20x
Pretax Margin (5Y Avg)-192.91%
Revenue / Share (Annual)$2.27
Tangible BV / Share (Annual)$0.71
Forward P/E3.79x
Price vs S&P 500 (52W)24.09%
P/E Ratio (TTM)11.10x
Year-to-Date Return-35.79%
5-Day Price Return0.00%
EPS Normalized (Annual)$0.24
ROA (5Y Avg)-22.03%
Net Profit Margin (Annual)10.77%
Month-to-Date Return-15.77%
Cash Flow / Share (TTM)$-25.80
EBITD / Share (Annual)$-0.76
Operating Margin (Annual)-68.12%
LT Debt / Equity (Annual)1.19x
ROI (5Y Avg)-44.39%
P/E Excl Extra (TTM)11.10x
LT Debt / Equity (Quarterly)1.19x
EPS Basic Excl Extra (TTM)$0.17
P/TBV (Quarterly)5.10x
Payout Ratio (Annual)9.74%
P/B Ratio (Annual)2.28x
Dividend / Share (TTM)$0.02
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)-53.28%
Book Value / Share (Annual)$1.59
Price vs S&P 500 (13W)-40.88%
Dividend Yield (TTM)0.88%
Beta1.22x
Revenue / Share (TTM)$2.08
ROE (TTM)15.86%
52-Week Low$1.45
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FBIOPFortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | 1.20x | 9.69% | 66.92% | — | $13.12 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Fortress Biotech acquires and commercializes pharmaceutical and biotechnology products, with a focus on dermatology. The company generates the majority of its revenue from dermatology products including Qbrexza, Accutane, Amzeeq, Zilxi, and Exelderm. Through its subsidiaries, Fortress also develops products in oncology and other therapeutic areas.